Sort
82,697 grants matching “vaccine development”
TASK A-1: NIH TETRAMER CORE FACILITY (INFECTIOUS DISEASES OTHER THAN HIV/AIDS)
$860,000John Altman · Emory University · N01 · FY2023 · AI
Nucleoside modified mRNA based HIV vaccine
$859,974Drew Weissman · University Of Pennsylvania · R01 · FY2016 · AI
SPORE in Myeloid Malignancies
$859,786Benjamin Levine Ebert · Dana-Farber Cancer Inst · P50 · FY2018 · CA
Population genotyping of the germline immunoglobulin repertoire in AIDS-designated rhesus macaque breeding colonies
$859,777Steven Edward Bosinger · Emory University · R24 · FY2024 · AI
Population genotyping of the germline immunoglobulin repertoire in AIDS-designated rhesus macaque breeding colonies
$859,777Steven Edward Bosinger · Emory University · R24 · FY2023 · AI
Population genotyping of the germline immunoglobulin repertoire in AIDS-designated rhesus macaque breeding colonies
$859,777Steven Edward Bosinger · Emory University · R24 · FY2022 · AI
DEVELOPMENT OF A RECOMBINANT CSPZ VACCINE AGAINST LYME DISEASE INFECTION
$859,758Baylor College Of Medicine · · FY2020 · Defense Health Agency
Eliciting Broadly Neutralizing Antibody Responses against HIV-1 Fusion Peptide Epitope by AB Toxin B Subunit-Based Immunogens
$859,597Xiangpeng Kong · New York University School Of Medicine · R01 · FY2024 · AI
Identification and validation of influenza host factors as therapeutic targets
$859,564David E Root · Broad Institute, Inc. · U01 · FY2011 · AI
Targeted genetic engineering of B cells to induce protective antibody responses to viral pathogens
$859,486Jennifer Eileen Adair · Fred Hutchinson Cancer Center · R01 · FY2023 · AI
Investigating the Protective Efficacy of SIV/HIV T and B cell Immunity Induced by ChAd and mRNA
$859,455Gaurav Das Gaiha · Massachusetts General Hospital · R01 · FY2024 · AI
Pediatric AIDS Clinical Trials Group
$859,411University Of California San Diego · U01 · FY2002 · AI
Nikkomycin Z treatment of primary pneumonia due to Coccidioides
$859,330David Larwood · Valley Fever Solutions, Inc. · U01 · FY2016 · AI
COVID-19: Assay Development, HTS and Drug Repurposing to identify potential therapeutics against SARS-CoV-2
$859,275Matthew Hall · National Center For Advancing Translational Sciences · ZIA · FY2020 · TR
PROTECTIVE MECHANISMS WITH ATTENUATED LENTIVIRAL VACCINE
$859,182University Of California Davis · R01 · FY2001 · AI
Trans-complementing papillioma virus for AIDS vaccine
$859,068Marie-Claire Elisabeth Gauduin · Texas Biomedical Research Institute · R01 · FY2018 · AI
Evaluation of Antibody Responses Elicited by Zika Vaccination in Flavivirus-naïve and -experienced Individuals
$859,058Shelly J Krebs · Henry M. Jackson Fdn For The Adv Mil/Med · R01 · FY2022 · AI
High-throughput mapping of antigen specificity to B-cell-receptor sequence for characterizing antibody responses in HIV-vaccinated and infected individuals
$859,004Ivelin Georgiev · Vanderbilt University Medical Center · R01 · FY2021 · AI
Optimizing glycan shield coverage, germline B cell receptor binding and epitope diversity of V2-apex targeted HIV-1 Env immunogens
$858,966Beatrice H Hahn · University Of Pennsylvania · R37 · FY2021 · AI
High-throughput immunoproteomics for cancer biomarker discovery
$858,891Joshua Labaer · Arizona State University-Tempe Campus · U2C · FY2024 · CA
Harnessing native glycosylation to improve immunogenicity of HIV-1 Env immunogens
$858,835Chitra Upadhyay · Icahn School Of Medicine At Mount Sinai · R01 · FY2024 · AI
Role of B Lymphocytes In HIV Infection And Pathogenesis
$858,726Susan Moir · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
HIV-1 Env Trimer Crystallography
$858,618Ian A Wilson · Progenics Pharmaceuticals, Inc. · P01 · FY2009 · AI
A therapeutic vaccine for chronic hepatitis B
$858,609David R. Milich · Vlp Biotech, Inc. · R44 · FY2020 · AI
A multivalent prophylactic and therapeutic vaccine against EBV infection and EBV-associated malignancies
$858,605Javier Gordon Ogembo · Beckman Research Institute/City Of Hope · R56 · FY2020 · AI